Hoth Therapeutics Inc. (NASDAQ: HOTH) shares gained 12.9% after the company signed a Sponsored Research Agreement with Washington University to support research and development of HT-ALZ- HT-ALZ is a novel treatment for Alzheimer’s disease symptoms.
Hoth Therapeutics partners with Washington University School of Medicine
Washington University School of Medicine’s Carla Yuede, Ph.D., Associate Professor of Psychiatry, and John Cirrito, Ph.D., Associate Professor of Neurology, will lead the study. The link between synaptic activity and amyloid-beta metabolism in Alzheimer’s disease has been the focus of Dr. Cirrito’s study. The formation of toxic oligomers and plaques of Amyloid-beta (Abeta) peptide within the brain is thought to be the l cause of Alzheimer’s disease. Dr. Yuede’s study focuses on the elements that influence cognitive function and brain Aß dynamics in Alzheimer’s disease animal models, notably synaptic activity.
Hoth Therapeutics CE Robb Knie said they are delighted to expand the AD research through the collaboration with Dr. John Cirrito, Dr. Carla Yuede, and Washington University. He said that they are excited about HT-ALZ’s potential impact on Alzheimer’s disease treatment. Hoth Therapeutics’ focus is developing innovative and novel therapeutics to address unmet patient needs and drive shareholder value.
Yuede said that the collaboration with Hoth Therapeutics explores a novel path towards treating Alzheimer’s disease symptoms in preclinical models. He added that they are delighted with the possibility of the new understanding in the treatment of AD.
Hoth announce positive preclinical study results
The company recently announced that it will share promising results from a preclinical study reinforcing HT-KIT’s potential. HT-KIT is a molecular entity the company is developing for anaphylaxis and mast cell derived-cancers treatment. The company conducted the preclinical trials using humanized mast cell neoplasm models and mast cell-derived cancers such as mast cell sarcoma and mast cell leukemia.